Discontinuation of etanercept after clinical remission in patients with juvenile idiopathic arthritis

Discontinuation of etanercept after clinical remission in patients with juvenile idiopathic arthritis

Bibliographic Details
Main Authors:	Cohen Jean-David, Fournet Dominique, Ludwig Catherine, Bozonnat Marie-Cécile, Rodiere Michel, Jorgensen Christian
Format:	Article
Language:	English
Published:	BMC 2012-07-01
Series:	Pediatric Rheumatology Online Journal
Online Access:	http://www.ped-rheum.com/content/10/S1/A51

Similar Items

Genetic markers in clinical subtypes of juvenile idiopathic arthritis
by: Le Blay Pierre, et al.
Published: (2011-11-01)

Etanercept discontinuation in a cohort of juvenile idiopathic arthritis patients: etanercept inefficacy but not intolerance is associated with oral corticosteroid use
by: Southwood TR, et al.
Published: (2008-09-01)

Etanercept in juvenile idiopathic arthritis: Who will benefit?
by: van den Berg JM, et al.
Published: (2011-09-01)

USE OF ETANERCEPT IN PATIENTS WITH OLIGOARTICULAR JUVENILE IDIOPATHIC ARTHRITIS
by: Т. М. Bzarova, et al.
Published: (2014-12-01)

Bilateral Panuveitis at Etanercept Initiation for Juvenile Idiopathic Arthritis
by: Kaouther Ben Abdelghani, et al.
Published: (2014-03-01)

EFFICACY OF ETANERCEPT IN TREATMENT OF VARIOUS TYPES OF JUVENILE IDIOPATHIC ARTHRITIS
by: O. Yu. Konopel'ko, et al.
Published: (2013-12-01)

ETANERCEPT TREATMENT RESULTS IN CHILDREN WITH NON-SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS: REMISSION, RECRUDESCENCE, AND ADVERSE EVENTS. RETROSPECTIVE COHORT STUDY
by: Mikhail M. Kostik, et al.
Published: (2018-05-01)

ASSESSMENT OF THE QUALITY OF LIFE OF PATIENTS WITH THE JUVENILE IDIOPATHIC ARTHRITIS TREATED BY THE ETANERCEPT
by: A. N. Fetisova, et al.
Published: (2014-07-01)

The efficacy and safety profile of biologic therapy with etanercept in juvenile idiopathic arthritis
by: Siamopoulou-Mavridou A, et al.
Published: (2011-09-01)

Evaluation of Efficacy and Safety of Etanercept and Etanercept + Methotrexate Therapy in Patients with Juvenile Idiopathic Arthritis without Systemic Manifestations
by: T. M. Bzarova, et al.
Published: (2016-01-01)

ETANERCEPT IN THE REAL CLINICAL PRACTICE OF TREATMENT IN PATIENTS WITH ACTIVE JUVENILE IDIOPATHIC ARTHRITIS
by: Elena Spartakovna Zholobova, et al.
Published: (2013-02-01)

Dynamics of concomitant therapy in children with juvenile idiopathic arthritis treated with etanercept and methotrexate
by: Ekaterina Alexeeva, et al.
Published: (2019-10-01)

Patterns of etanercept use in juvenile idiopathic arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry
by: Timothy Beukelman, et al.
Published: (2021-08-01)

<it>In vitro</it> effects of etanercept on the development of different T cell subsets in patients with juvenile idiopathic arthritis
by: Liotta Francesco, et al.
Published: (2011-09-01)

When and how to stop etanercept after successful treatment of patients with juvenile idiopathic arthritis
by: Prince FHM, et al.
Published: (2008-09-01)

The impact of a 2-year Etanercept administration on growth of patients with juvenile idiopathic arthritis
by: Kaitalidou E, et al.
Published: (2011-09-01)

Using etanercept to maintain remission of psoriatic arthritis during pregnancy
by: Ibrahim A Al-Homood, et al.
Published: (2014-01-01)

Etanercept for patients with juvenile idiopathic arthritis: drug levels and influence of concomitant methotrexate: observational study
by: Tiina Levälampi, et al.
Published: (2023-03-01)

Early Prediction of Clinical Response to Etanercept Treatment in Juvenile Idiopathic Arthritis Using Machine Learning
by: Xiaolan Mo, et al.
Published: (2020-07-01)

Bone mineral density in children with juvenile idiopathic arthritis after one year of treatment with etanercept
by: Sušić Gordana, et al.
Published: (2018-01-01)

The immune response mediator genes polymorphic variants as predictors of the etanercept efficacy in juvenile idiopathic arthritis
by: Liliia Sh. Nazarova, et al.
Published: (2018-05-01)

A systematic review of effectiveness and economic evaluation of new drug treatments for juvenile idiopathic arthritis: etanercept.
by: Cummins, C, et al.
Published: (2002)

A systematic review of effectiveness and economic evaluation of new drug treatments for juvenile idiopathic arthritis: etanercept.
by: Cummins, C, et al.
Published: (2002)

Plasma Glycosaminoglycans in Children with Juvenile Idiopathic Arthritis Being Treated with Etanercept as Potential Biomarkers of Joint Dysfunction
by: Magdalena Wojdas, et al.
Published: (2022-07-01)

Concomitant Use of Elexacaftor/Tezacaftor/Ivacaftor and Etanercept in a Cystic Fibrosis Patient with Juvenile Idiopathic Arthritis
by: Sara Immacolata Orsini, et al.
Published: (2023-02-01)

The effect of etanercept therapy on adrenal steroid metabolism in juvenile idiopathic arthritis: a steroid metabolomics approach
by: Yonatan Butbul Aviel, et al.
Published: (2023-04-01)

LONG TERM FOLLOW-UP ON EFFECTIVENESS AND SAFETY OF ETANERCEPT IN JUVENILE IDIOPATHIC ARTHRITIS WITHOUT SYSTEMIC MANIFESTATIONS
by: A. A. Baranov, et al.
Published: (2015-04-01)

Improvement of DAS-28 ESR score in Egyptian children and adolescents with juvenile idiopathic arthritis treated with etanercept
by: Rasha Abdel-Raouf Afifi, et al.
Published: (2017-07-01)

Correlation of ultrasonography synovitis with disease activity and clinical response to etanercept treatment in juvenile idiopathic arthritis patients
by: Li Zhou, et al.
Published: (2019-11-01)

Can remission be in juvenile idiopathic arthritis without the use of biological agents?
by: S. I. Valieva, et al.
Published: (2019-09-01)

Etanercept In the treatment of AA-amyloidosis in juvenile rheumatoid arthritis
by: H Mihels
Published: (2004-08-01)

Evaluation of Efficacy and Safety of Etanercept Therapy in Patients with Early and Late Juvenile Idiopathic Arthritis without Systemic Manifestations
by: T. M. Bzarova, et al.
Published: (2015-09-01)

The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis
by: Yoshiya Tanaka, et al.
Published: (2019-07-01)

Subclinical cardiovascular risk signs in adults with juvenile idiopathic arthritis in sustained remission
by: Inmaculada Concepción Aranda-Valera, et al.
Published: (2020-07-01)

Articular Doppler ultrasonography in juvenile idiopathic arthritis in remission: a prospective study
by: Natour Jamil, et al.
Published: (2011-09-01)

Evaluation of effectiveness and safety of Etanercept in children with Juvenile psoriatic arthritis
by: K. V. Aleksanyan, et al.
Published: (2020-09-01)

Early Prognostic Factors for Remission Achievement at Etanercept Therapy in Patients with Juvenile Idiopatic Arthritis Without Systematic Manifestations: Prospective Cohort Study
by: Ekaterina I. Alexeeva, et al.
Published: (2019-04-01)

Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry
by: Gerd Horneff, et al.
Published: (2017-11-01)

EFFICACY OF ETANERCEPT IN CHILD WITH SEVERE POLYARTICULAR TYPE OF JUVENILE RHEUMATOID ARTHRITIS
by: T.M. Bzarova, et al.
Published: (2011-03-01)

EFFICACY OF ETANERCEPT IN CHILD WITH SEVERE POLYARTICULAR TYPE OF JUVENILE RHEUMATOID ARTHRITIS
by: T.M. Bzarova, et al.
Published: (2011-01-01)